Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.

@article{Herold2007RituximabAT,
  title={Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.},
  author={Michael Herold and Antje Haas and Stefanie Srock and Sabine Neser and Kathrin Haifa Al-Ali and Andreas Neubauer and Gottfried Doelken and Ralph Naumann and Wolfgang Ulrich Knauf and Mathias Freund and Robert Rohrberg and Klaus Hoeffken and Astrid Franke and Thomas H. Ittel and Erika Kettner and Ursula Haak and Ulrich J. M. Mey and Christian Klinkenstein and Michael Assmann and Ullrich von Gr{\"u}nhagen},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 15},
  pages={1986-92}
}
PURPOSE Rituximab has been shown to be active in follicular lymphoma (FL), both as monotherapy and in combination with chemotherapy. We conducted a randomized trial comparing mitoxantrone, chlorambucil, and prednisolone (MCP) chemotherapy plus rituximab with MCP alone. PATIENTS AND METHODS Previously untreated patients with stage III or IV CD20+ indolent or mantle cell lymphoma were randomly assigned to either eight 28-day cycles of MCP plus rituximab (R-MCP; n = 181) or eight cycles of MCP… CONTINUE READING
Highly Influential
This paper has highly influenced 13 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS